Pieris and Boston Pharmaceuticals Immuno-Oncology Collaboration
Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Boston Pharmaceuticals is responsible for further development of the program and the program is currently in a phase 1 clinical study.
Pipeline Chart
Immuno-Oncology
Candidate
Targets
Partner
Discovery
Preclinical
Phase 1
Phase 2
Candidate
PRS-342/BOS-342
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started